Insider Selling: CeriBell (NASDAQ:CBLL) Director Sells 16,714 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Josef Parvizi sold 16,714 shares of CeriBell stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $20.27, for a total transaction of $338,792.78. Following the transaction, the director owned 722,652 shares of the company’s stock, valued at $14,648,156.04. This represents a 2.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Josef Parvizi also recently made the following trade(s):

• On Thursday, January 15th, Josef Parvizi sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $22.94, for a total transaction of $573,500.00.
• On Monday, December 15th, Josef Parvizi sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $21.49, for a total transaction of $537,250.00.
• On Monday, December 8th, Josef Parvizi sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $20.26, for a total value of $506,500.00.

CeriBell Stock Down 1.6%

Shares of CBLL stock traded down $0.33 during trading hours on Monday, reaching $19.89. The company had a trading volume of 148,185 shares, compared to its average volume of 338,256. The company has a market cap of $737.92 million, a price-to-earnings ratio of -13.17 and a beta of 1.03. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25. CeriBell, Inc. has a 12 month low of $10.01 and a 12 month high of $26.04. The business has a fifty day simple moving average of $21.34 and a 200-day simple moving average of $16.07.

Institutional Trading of CeriBell

A number of large investors have recently added to or reduced their stakes in CBLL. Russell Investments Group Ltd. boosted its stake in CeriBell by 41.4% in the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock valued at $64,000 after acquiring an additional 854 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after purchasing an additional 1,231 shares during the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of CeriBell by 97.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after purchasing an additional 1,256 shares during the period. Deutsche Bank AG lifted its stake in CeriBell by 1.7% in the fourth quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after purchasing an additional 1,393 shares during the last quarter. Finally, Royal Bank of Canada grew its holdings in CeriBell by 10.8% during the fourth quarter. Royal Bank of Canada now owns 15,588 shares of the company’s stock valued at $342,000 after purchasing an additional 1,514 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on CBLL. JPMorgan Chase & Co. reduced their target price on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. TD Cowen restated a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. Canaccord Genuity Group increased their price objective on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, BTIG Research restated a “buy” rating and issued a $30.00 target price on shares of CeriBell in a research note on Wednesday, January 28th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, CeriBell has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.